Key result
CAC-guided counseling proves cost-effective at ~$6415/QALY for diabetics aged 60-69 not on statins.
Why the study?
Guidelines do not recommend CAC scans in adults with diabetes because they are uniformly considered statin-indicated, yet CV risk varies and CAC scans may help increase statin use.
Does CAC-guided risk counselling improve cost-effectiveness compared to traditional counselling for initiating statin therapy in adults with diabetes?
Does CAC-guided risk counselling improve cost-effectiveness compared to traditional counselling for initiating statin therapy in adults with diabetes?
CAC-guided risk counselling can be a cost-effective strategy to personalize cardiovascular risk and encourage statin use in select older adults with diabetes.
Answers are grounded in this paper and cite their sources.
CAC-guided statin use may better target higher-risk diabetes patients; modeling leaves open broad cost-effectiveness.
Many adults with diabetes are not on a statin.1 A coronary artery calcium (CAC) scan provides a depiction of coronary artery disease and is predictive of cardiovascular (CV) risk. Showing and discussing CAC scan findings with patients has been shown to increase the use of preventive medications.2, 3 Even in trials where CAC-based intervention reduced the use of statins (e.g., due to enrolment of healthier individuals at lower CV risk), the distribution of statin use shifted toward higher-risk individuals,4 with overall reductions in CV risk.2 CAC scans may be considered a form of personalized medicine, with incremental utility dependent on judicious patient selection.5, 6 Guidelines recommend the use of CAC scans in intermediate-risk individuals to help decide whether to start statin therapy. Since people aged ≥ 40 years with diabetes are uniformly considered statin-indicated, guidelines do not recommend CAC scans in adults with diabetes.7 However, CV risk can vary among adults with diabetes, and CAC scans may help to increase statin use.8 We performed an economic evaluation to explore the potential cost-effectiveness of CAC-guided risk counselling, compared to traditional risk factor counselling, among adults with diabetes who were not on statin therapy. We developed a Markov model of individuals with diabetes and no previous CV disease, who were not on statin therapy. Two age bands were chosen: men and women aged 60–69 years, consistent with the mean age of reported CAC cohorts,8 and men and women aged 40–49 years, the threshold for statin use in Canadian guidelines. The base cohort was men aged 60–69 years. Underlying CV risk without statin therapy was estimated from Alberta data. The distribution of CAC scores and the relative CV risk of each CAC score subgroup were derived from the published cohorts.8, 9 The intervention was CAC-guided counselling, while the control was traditional risk factor counselling. Their effects on statin use were obtained from the EISNER trial, which randomized individuals with CV risk factors to CAC-guided counselling or standard nurse practitioner counselling. Among those not on statin at baseline (n = 1482), the frequency of statin use after CAC-guided counselling was 22.9% overall, but ranged from 19% (CAC = 0) to 65% (CAC ≥ 400) depending on the revealed CAC score. We took this graded response to revealed CAC to be the effect of CAC-guided counselling. In contrast, the effect of traditional risk factor counselling was statin use in 25%, regardless of CV risk. Cost-effectiveness was evaluated from a Canadian healthcare payer perspective using probabilistic modelling (1000 re-samplings) over a 10-year horizon, with outcomes as shown (Figure 1). Statin use was assumed to reduce stroke and myocardial infarction risk. Health utility and costs (2020 Canadian dollars [CAD]) were estimated from literature and public sources. In Alberta, CAC scans are privately funded with a charge of $475 CAD.10 We considered CAC-guided risk counselling cost-effective if it improved outcomes at an incremental cost-effectiveness ratio (ICER) of < $50 000/quality-adjusted life-year (QALY) in >80% of re-samplings. One-way sensitivity analyses were performed, in addition to two scenario analyses: (1) we lowered the price of a CAC scan to $200 and (2) we simulated individuals who refuse statin therapy (control arm statin use = 0%), but would reconsider if shown a ‘positive’ CAC scan (intervention arm statin use 19%–65%, as above). Additional details are available in the supplementary material. Men aged 60–69 years provided with CAC-guided counselling would increase their overall statin use to 44% in a risk-dependent manner, compared to statin use of 25%, uniformly distributed across all risk categories among those provided with traditional risk factor counselling only. CAC-guided counselling was projected to lead to 8.4 fewer cases of acute coronary syndrome, 5.5 fewer strokes and 1.6 fewer deaths per 1000 individuals over 10 years. The number of additional scan-associated cancers was 8 per 100 000 individuals. The mean ICER was $6415/QALY (median $609/QALY; Table 1A), and <$50 000/QALY in 95% of simulations. Findings were sensitive to the proportion of patients who initiate and continue statin therapy in the traditional CV risk counselling arm. In women aged 60–69 years, CAC-guided risk counselling was cost-effective. For men aged 40–49 years and women aged 40–49 years, CAC-guided risk counselling was not cost-effective, due to lower CAC scores and CV risk in younger individuals (Table 1B). In the first scenario featuring a lower cost of CAC ($200), CAC-guided counselling became dominant (i.e., both cost-saving and more effective) for men and women aged 60–69 years (mean ICERs –$25 944 and –$17 999/QALY, respectively), and became cost-effective for men aged 40–49 years (mean ICER $4140/QALY). It was not cost-effective in women aged 40–49 years. In the second scenario of patients who had previously declined statin use, CAC score-based counselling similarly became dominant for men and women aged 60–69 years, and cost-effective for men aged 40–49 years. It was not cost-effective in women aged 40–49 years (Table 1B). Compared to traditional CV risk factor counselling alone, CAC-guided counselling was cost-effective for older men and women (aged 60–69 years). Scenario analyses demonstrated that CAC scoring could be dominant (cost-saving) in older men or women, and cost-effective in younger men (aged 40–49 years) if the cost of the procedure were $200 or less, as it is in some other jurisdictions (US pricing is as low as $100 USD11), or when considering specific patients who decline statin therapy (i.e., statin use 0%) with traditional counselling, but would re-consider if shown personalized CAC evidence of risk (e.g., statin use 19%–65%, in our model). The benefit of statin therapy for primary CV prevention is well established, yet the proportion of adults with diabetes taking a statin has plateaued.1 Although current guidelines treat diabetes uniformly, a spectrum of CV risk exists, which can be quantified and visualized by CAC scanning. The lower baseline CV risk in younger individuals and in women meant that the upfront cost of CAC, as it currently exists in Alberta ($475 CAD), was not offset by downstream reductions in CV events. In some age and sex groups, even among those with diabetes, the prevalence of high-risk CAC (scores 401–10 000) is low—half as much for women than men and roughly half as much for age 40–49 years than age 60–69 years.8, 9 However, under lower cost conditions, CAC scans can be more broadly cost-saving or cost-effective. Most importantly, if a provider can identify a specific patient who is unpersuaded by traditional counselling, but would re-consider statin use if shown personalized evidence of coronary artery disease, CAC-guided counselling would be similarly cost-saving or cost-effective. Our findings are predicated on the effectiveness of CAC-guided counselling versus traditional risk factor counselling, which was extrapolated from the EISNER trial, performed over 10 years ago, in the United States, in a population in which a minority of adults had diabetes. Trial data that apply directly to adults with diabetes are unavailable. Notably, approximately 59% of patients not on a statin cannot recall having been offered one.12 Therefore, there may be a large potential gain from simply recalling these patients and revisiting CV risk, prior to CAC scanning. Our results support a potential role for the individualized use of CAC scanning, in the context of a therapeutic relationship, to advance a rational, risk-based conversation about statin use. CAC scanning can be a cost-effective tool for personalizing CV risk, in select individuals with diabetes, not on statin therapy. Darren Lau conceived the study, arranged data access, analysed the results, and drafted this manuscript. All authors have contributed substantial intellectual content to the design of the study and interpretation of results, and have made critical revisions to the final manuscript. This study is partly based on data provided by Alberta Health and Alberta Precision Laboratories. The interpretation and conclusions are those of the researchers and do not necessarily represent the views of the Government of Alberta. Neither the Government of Alberta nor Alberta Health express any opinion in relation to this study. This study was funded using research start-up funds held by Dr. Lau and provided by the Department of Medicine at the University of Alberta. The authors have no conflicts of interest related to the content of this article. The peer review history for this article is available at https://www.webofscience.com/api/gateway/wos/peer-review/10.1111/dom.15558. The Alberta data involved in this study is governed by provincial legislation and is not available for sharing or re-use. Data S1. Supporting information. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
No takes yet. Share an insight, caveat, or question.
Lau et al. (2024) studied Type 2 diabetes without previous cardiovascular disease. CAC-guided risk counselling vs. Traditional risk factor counselling was evaluated on Incremental cost-effectiveness ratio (ICER) (mean ICER $6415/QALY). CAC-guided risk counselling was cost-effective for adults aged 60-69 years with diabetes not on statins (mean ICER $6415/QALY), but not for those aged 40-49 years at standard scan costs.
Synapse has enriched 10 related papers. Consider them for comparative context: